Prednisone treatment in acute interstitial nephritis - a randomized prospective trial (PRAISE)

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-520299-86-00

Acronym

FHM-1-2017

Enrollment

110

Registered

2025-01-13

Start date

2025-01-22

Completion date

Unknown

Last updated

2025-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute interstitial nephritis

Brief summary

eGFR at 3 months

Detailed description

Kidney function (eGFR) at 12 months, CKD stage, Number og patients in dialysis, Effekt of treatment-delay on outcome, Urinary biomarkers, Questionaire: SF36 score, The predictive value of histopathological evaluation, Safety endpoints: P-glukose, Infections, Submissions

Interventions

DRUGPrednisolon "DAK"

DRUGtabletter

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
eGFR at 3 months	—

Secondary

Measure	Time frame
Kidney function (eGFR) at 12 months, CKD stage, Number og patients in dialysis, Effekt of treatment-delay on outcome, Urinary biomarkers, Questionaire: SF36 score, The predictive value of histopathological evaluation, Safety endpoints: P-glukose, Infections, Submissions	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026